THE SCIENCE

Advancing Precision Serotonergic Therapeutics

We develop highly targeted compounds that uniquely modulate serotonergic signaling with reduced safety and tolerability risks, addressing diseases with unmet vascular and neuropsychiatric needs.

OUR PIPELINE

2025

Discovery + Lead Series

5HT2A Inhibitor

Indications: Alzheimer’s and Parkinson’s Associated Dementia

5HT2B Antagonist

Indication: Raynaud’s Phenomena

Novel

Indications: Vasculopathies

2026

Lead Candidate

5HT2A Inhibitor

Indications: Alzheimer’s and Parkinson’s Associated Dementia

5HT2B Antagonist

Indication: Raynaud’s Phenomena

Key Activities:

IND-enabling Studies
CMC
IND Filing
Regulatory Strategy

2027 – 2028

Drug Candidate

5HT2A Inhibitor

Indications: Alzheimer’s and Parkinson’s Associated Dementia

5HT2B Antagonist

Indication: Raynaud’s Phenomena

Key Activities:

IND Cleared / Clinical Entry
Trial Sites
Phase I (Safety/PK)
Phase IIa (Proof-of-Concept)
Early Clinical Data

2028 – 2030

Phase II Completion + Phase III Initiation

5HT2A Inhibitor

Indications: Alzheimer’s and Parkinson’s Associated Dementia

5HT2B Antagonist

Indication: Raynaud’s Phenomena

Key Activities:

Proof-of-Concept Data
Expanded Safety Dataset
Registration Strategy

OUR DIFFERENCE

From Vanderbilt Discovery to Clinical Development

Sero Pharmaceuticals is developing highly selective serotonergic therapies to address diseases with significant unmet needs in neurovascular and neuropsychiatric areas.

Built on discoveries from the Vanderbilt University Warren Center, our platform focuses on next-generation compounds designed to modulate serotonin pathways with improved safety and specificity.

Our team is advancing a pipeline of targeted programs toward clinical development to deliver meaningful new treatment options for patients.

THERAPEUTIC PROGRAMS

Two Targeted Programs Addressing High-Unmet Neurological and Vascular Diseases

5HT2A / AD–PD Dementia

We are developing a next-generation 5HT2A inhibitor designed to treat neuropsychiatric symptoms associated with Alzheimer’s disease and Parkinson’s disease dementia. By selectively modulating serotonergic signaling in the brain, this program aims to improve safety and tolerability while addressing significant unmet needs in dementia-related psychosis.

5HT2B / Vasculopathies

Our 5HT2B antagonist program, discovered at the Vanderbilt University Warren Center, targets serotonin signaling pathways linked to vascular dysfunction. These highly selective compounds are being developed to address serious vasculopathies, such as Scleroderma, and could deliver a new therapeutic approach for patients with limited treatment options.

MARKET OPPORTUNITY

Large Market Opportunities Across Two Therapeutic Areas

Vascular Disease Market Opportunity
(Raynaud’s, Scleroderma, Pulmonary Arterial Hypertension)

$ 0 B+

Neuropsychiatric Market Opportunity
(Alzheimer’s & Parkinson’s Disease Psychosis)

$ 0 B+

Contact Us

Partner With Us to Shape the Future of Serotonergic Therapeutics

We invite investors, collaborators, and the research community to connect with Sero Pharmaceuticals. By working together, we can advance serotonergic science and deliver meaningful progress for patients.

Name

First Last

Phone

Message